IsoRay

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

IsoRay (ISR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

IsoRay (ISR) Upgraded to Buy: What Does It Mean for the Stock?

RICHLAND, Wash., June  02, 2020  (GLOBE NEWSWIRE) --   Isoray, Inc.  (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal radiation therapy (brachytherapy).  The observational study from the University of Pittsburgh School of Medicine followed a large group of patients for up to ten years. Using a biochemical endpoint*, the data show the ten year success rates for treatment with Cesium-131 were 95.3% for patients in the low-risk category (200 patients under study), 90.1% for patients in the intermediate-risk category (372 patients under study) and 56.6% for 97 high-risk patients. Patients with higher risk cancers were treated with external beam radiation therapy in addition to their Cesium-131 implant, while lower risk patients underwent only a Cesium-131 implant.  

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2020 Results - Earnings Call Transcript

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year

Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

RICHLAND, Wash., May  12, 2020  (GLOBE NEWSWIRE) --  Isoray, Inc.  (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient DRG setting. The codes allow hospitals to bill Medicare and other health insurers for specific surgical procedures that would benefit from the addition of Cesium-131. DRG or diagnostic related groups are designed for Medicare and other health insurers to set payment levels for hospital in-patient services.

Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About IsoRay (ISR) Rating Upgrade to Strong Buy

IsoRay Is Set For Further Growth

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IsoRay (ISR) Upgraded to Buy: Here's What You Should Know

IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2020 Results - Earnings Call Transcript

IsoRay: Turned Around And Growing

Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options

Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers

IsoRay Likely Has Further To Rise

What Makes IsoRay (ISR) a New Strong Buy Stock

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2020 Results - Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of 50.00% and 4.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q1 Loss, Tops Revenue Estimates

Isoray, Inc. (NYSE AMERICAN: ISR)  announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place November 1-2 at the Hyatt Regency Denver at Colorado Convention Center in Denver, Colorado.

Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2019 Results - Earnings Call Transcript

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy

Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2%Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date

A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

RICHLAND, WASHINGTON, Sept.  10, 2019  (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer treatment applications of Cesium-131 at the American Society for Radiation Oncology (ASTRO) annual meeting. The meeting will be held September 15-18 at McCormick Place in Chicago, Illinois.

Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting 

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2019 Results - Earnings Call Transcript

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for IsoRay Stock (ISR)